Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression

Background: Esketamine has been approved by the US Food and Drug Administration (FDA) as an adjunctive treatment for use in conjunction with an oral antidepressant for patients with treatment-resistant depression (TRD), but dissociative symptoms are common adverse effects. Methods: A retrospective a...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Sant, Lorena Catarina, Sarin, Luciana Maria, Lucchese, Ana Cecília, Magalhães, Eduardo Jorge Muniz, Tuena, Marco Aurélio, Nakahira, Carolina, Del Porto, José Alberto, De Lacerda, Acioly Luiz Tavares, Mari, Jair de Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861342/
https://www.ncbi.nlm.nih.gov/pubmed/36678528
http://dx.doi.org/10.3390/ph16010031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861342/
https://www.ncbi.nlm.nih.gov/pubmed/36678528
http://dx.doi.org/10.3390/ph16010031

Ejemplares similares